Make it Right: Put people over profits!
Paul Hudson, CEO of Sanofi; Lars Fruergaard Jørgensen President and CEO of Novo Nordisk; and David Ricks, CEO of Eli Lilly
Across the world, people living with diabetes who rely on insulin to survive ask the question: “Can I afford to live today?”
Living with diabetes comes with many challenges. Financially, it can take over 50% of a person’s income just to afford insulin and testing supplies. Emotionally, the impossible choice between buying medicine or paying for housing, food, or education often forces people to ration their insulin. Managing blood sugar levels also means making about 180 extra decisions each day, adding yet another layer of stress. All of this only deepens the realities of diabetes burnout. Many of us cannot afford everything we need to live well with diabetes — whether it’s money, time or energy.
This is not our fault. For too long, Big Pharma has prioritized profits over people’s lives, charging exorbitant prices for insulin and other essentials. It’s time to make it right. Insulin and testing supplies need to be priced so that people with diabetes can access the quality care they need while still being able to afford other essentials.
To live healthy lives, we need insulin that is affordable and accessible to all and in a delivery device that promotes quality of life for everyone. Insulin users say pens are preferred over vials and syringes. That’s why we’re calling on insulin manufacturers to lower the prices of all (human and analogue) insulin pens to $1/pen.
We need your voice. By signing this petition, you’re joining a global movement to demand that insulin manufacturers make it right for people with diabetes and lower insulin prices. Together, we can make a difference and ensure that no one has to ask whether they can afford to live another day.
By signing, you are agreeing to have your name and country, as well as your state if you are in the United States, to be shared publicly.
Sponsored by
To:
Paul Hudson, CEO of Sanofi; Lars Fruergaard Jørgensen President and CEO of Novo Nordisk; and David Ricks, CEO of Eli Lilly
From:
[Your Name]
We believe that everyone with diabetes, no matter where they live, has everything they need to survive and achieve their dreams. No one should have to spend more than 5% of their income on essential insulin and glucose testing supplies. You can make it right.
Countries need to have access to affordable insulin to be able to provide it to their people with diabetes. That’s why we’re calling on all insulin manufacturers to make all of their insulins that are on the WHO’s Essential Medicines List available for government contract for $5 or less for a box of pens in low and middle income countries.
Paul Hudson, CEO of Sanofi; Lars Fruergaard Jørgensen President and CEO of Novo Nordisk; and David Ricks, CEO of Eli Lilly—please make it right and commit to making lower priced insulin affordable for countries by 2025.